【摘要】：目的探討左西孟旦對晚期心力衰竭患者左心室功能、神經(jīng)激素水平及生存率的影響。方法 2010年5月至2015年6月在該院心內(nèi)科住院診斷為心力衰竭的患者160例,分為干預(yù)組、對照組。干預(yù)組在常規(guī)抗心力衰竭治療基礎(chǔ)上給予加用左西孟旦治療,對照組僅給予常規(guī)抗心力衰竭治療。所有患者住院次日清晨及出院前空腹采集靜脈血,檢驗血清BNP、內(nèi)皮素-1、血管緊張素Ⅱ及去甲腎上腺素,住院次日給予完善心臟超聲檢查。所有患者均給予定期隨訪。結(jié)果兩組患者治療后左心功能及神經(jīng)激素水平均較治療前改善。與對照組相比,左西孟旦組治療后左心功能恢復(fù)更好:左室射血分數(shù)較對照組顯著升高、血清BNP水平較對照組顯著下降;左西孟旦組血清內(nèi)皮素-1、血管緊張素Ⅱ及去甲腎上腺素水平均較對照組下降更顯著。COX風險比例回歸分析結(jié)果顯示,在調(diào)整血壓、心率、疾病史、用藥史及吸煙飲酒史后,左西孟旦組死亡風險較對照組降低(HR=0.98,95%CI:0.65~0.99)。結(jié)論左西孟旦治療心力衰竭不僅可在短期內(nèi)改善血清神經(jīng)激素水平、改善心功能,1年后仍可繼續(xù)改善心功能并改善預(yù)后、提高生存率。
[Abstract]:Objective to investigate the effects of levosimendan on left ventricular function, neurohormone level and survival rate in patients with advanced heart failure. Methods from May 2010 to June 2015, 160 patients with heart failure were divided into intervention group and control group. The intervention group was treated with levosimendan on the basis of routine anti-heart failure therapy, while the control group was only treated with routine anti-heart failure therapy. Venous blood was collected early in the next day of hospitalization and before discharge. Serum BNP-1, angiotensin 鈪，

本文編號：2133959